Advances in Molecular Pathogenesis, Precision Medicine, and Artificial Intelligence in Hematologic Malignancies

Dear Colleagues,

Hematologic malignancies represent a diverse group of cancers affecting blood, bone marrow, and lymphatic systems, characterized by complex molecular landscapes, diverse clinical courses, and evolving therapeutic challenges.

Recent advances in molecular biology and high-throughput technologies have unraveled critical pathways underlying leukemogenesis, lymphomagenesis, and marrow failure syndromes, providing unprecedented opportunities for risk stratification and targeted intervention. Precision medicine, driven by genomic and epigenomic profiling, has already transformed the management of several entities, enabling personalized therapeutic strategies that improve outcomes while minimizing toxicity

Recent decades have witnessed unprecedented advances in our understanding of the molecular underpinnings of these diseases, providing unprecedented opportunities for risk stratification and targeted intervention.

At the same time, artificial intelligence (AI) is emerging as a powerful tool in hematology, complementing traditional approaches by integrating multi-omic data, digital pathology, and real-world clinical information to enhance diagnosis, prognosis, and treatment selection. These advances not only accelerate translational research but also hold the promise of redefining clinical practice in the near future.

This Special Issue, Advances in Molecular Pathogenesis, Precision Medicine, and Artificial Intelligence in Hematologic Malignancies, invites original research articles, comprehensive reviews, and translational studies that explore the interplay between molecular mechanisms and innovative technologies. By bringing together insights from basic, translational, and clinical research, we aim to highlight breakthroughs that will shape the future of personalized hematology and improve patient care.

Dr. Eleftheria Hatzimichael
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diseases is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.